The role of antigen-presenting cells in triggering graft-versus-host disease and graft-versus-leukemia
R Chakraverty, M Sykes - Blood, The Journal of the American …, 2007 - ashpublications.org
After allogeneic blood or bone marrow transplantation, donor T cells interact with a distorted
antigen-presenting cell (APC) environment in which some, but not all, host APCs are …
antigen-presenting cell (APC) environment in which some, but not all, host APCs are …
Dendritic cells and regulation of graft-versus-host disease and graft-versus-leukemia activity
Hematopoietic stem cell transplantation is the only curative treatment for many malignant
hematologic diseases, with an often critical graft-versus-leukemia effect. Despite …
hematologic diseases, with an often critical graft-versus-leukemia effect. Despite …
Donor CD4+ Foxp3+ regulatory T cells are necessary for posttransplantation cyclophosphamide-mediated protection against GVHD in mice
S Ganguly, DB Ross… - Blood, The Journal …, 2014 - ashpublications.org
Posttransplantation cyclophosphamide (PTCy) is an effective prophylaxis against graft-
versus-host disease (GVHD). However, it is unknown whether PTCy works singularly by …
versus-host disease (GVHD). However, it is unknown whether PTCy works singularly by …
MyD88/TLR9 mediated immunopathology and gut microbiota dynamics in a novel murine model of intestinal graft-versus-host disease
MM Heimesaat, A Nogai, S Bereswill, R Plickert… - Gut, 2010 - gut.bmj.com
Background The bacterial microflora aggravates graft-versus-host-disease (GvHD) after
allogeneic stem cell transplantation, but the underlying mechanisms of manifestations of …
allogeneic stem cell transplantation, but the underlying mechanisms of manifestations of …
[HTML][HTML] Defining a TCF1-expressing progenitor allogeneic CD8+ T cell subset in acute graft-versus-host disease
S Lee, K Lee, H Bae, K Lee, J Lee, J Ma, YJ Lee… - Nature …, 2023 - nature.com
Graft-versus-host disease (GvHD) is a severe complication of hematopoietic stem cell
transplantation driven by activated allogeneic T cells. Here, we identify a distinct subset of T …
transplantation driven by activated allogeneic T cells. Here, we identify a distinct subset of T …
[HTML][HTML] HLA-haploidentical donor lymphocyte infusions for patients with relapsed hematologic malignancies after related HLA-haploidentical bone marrow …
Abstract Treatment of relapse after related HLA-haploidentical T cell–replete bone marrow
transplantation (haploBMT) with post-transplantation cyclophosphamide (PTCy) using …
transplantation (haploBMT) with post-transplantation cyclophosphamide (PTCy) using …
[HTML][HTML] Murine models of chronic graft-versus-host disease: insights and unresolved issues
YW Chu, RE Gress - Biology of Blood and Marrow Transplantation, 2008 - Elsevier
Chronic graft-versus-host-disease (cGVHD) is a major barrier to successful allogeneic
hematopoietic stem cell transplantation (allo-HSCT), with highly variable clinical …
hematopoietic stem cell transplantation (allo-HSCT), with highly variable clinical …
STAT3 signaling in CD4+ T cells is critical for the pathogenesis of chronic sclerodermatous graft-versus-host disease in a murine model
V Radojcic, MA Pletneva, HR Yen, S Ivcevic… - The journal of …, 2010 - journals.aai.org
Donor CD4+ T cells are thought to be essential for inducing delayed host tissue injury in
chronic graft-versus-host disease (GVHD). However, the relative contributions of distinct …
chronic graft-versus-host disease (GVHD). However, the relative contributions of distinct …
[HTML][HTML] Interplay between the intestinal microbiota and acute graft-versus-host disease: experimental evidence and clinical significance
T Hong, R Wang, X Wang, S Yang, W Wang… - Frontiers in …, 2021 - frontiersin.org
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative
therapy for many hematological disorders and autoimmune diseases, but acute graft-versus …
therapy for many hematological disorders and autoimmune diseases, but acute graft-versus …
[HTML][HTML] The graft versus leukemia effect: Donor lymphocyte infusions and cellular therapy
K Maurer, JH Antin - Frontiers in Immunology, 2024 - frontiersin.org
Allogeneic hematopoietic stem cell transplantation (HSCT) is a potentially curative therapy
for many hematologic malignancies as well as non-malignant conditions. Part of the curative …
for many hematologic malignancies as well as non-malignant conditions. Part of the curative …